Intersect ENT Profit Margin 2013-2018 | XENT
Current and historical gross margin, operating margin and net profit margin for Intersect ENT (XENT) over the last 10 years. Profit margin can be defined as the percentage of revenue that a company retains as income after the deduction of expenses. Intersect ENT net profit margin as of December 31, 2018 is -21.13%.
|Intersect ENT Annual Profit Margins
|Intersect ENT Quarterly Profit Margins
||Medical Instruments Manufacturing
Intersect ENT, Inc. is a commercial drug-device company. The Company's initial products, PROPEL and PROPEL mini, are drug-eluting implants for use in patients with chronic sinusitis. It offers products and therapies for ear, nose, and throat surgeons to improve treatment for their patients with chronic diseases. Intersect ENT, Inc. is headquartered in Menlo Park, California.